Interim / Quarterly Report • Aug 28, 2015
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
INTERIM REPORT JANUARY 1–JUNE 30, 2015
"Our success with RayStation® continues and the strong start to the year remains unabated. During the first half of the year, revenues from RayStation® rose approximately 129 percent to SEK 116.6 M (50.9). Overall, revenues rose 56.0 percent to SEK 165.1 M (105.8) and operating profit increased to SEK 31.0 M (8.4), representing the highest-ever sales and earnings for the first half-year," says Johan Löf, CEO of RaySearch.
"In the third quarter, we have already secured several key orders from some of the world's largest and most respected cancer clinics, including MD Anderson and the University of Florida Health Proton Therapy Institute in the US, and Gustave Roussy in France. We secured these orders in direct competition with our main competitors, which I consider firm confirmation that our system offers major benefits," says Johan Löf.
| AMOUNTS IN SEK 000S | JAN-JUN | APR-JUN | JUL 2014- | FULL-YEAR | ||
|---|---|---|---|---|---|---|
| 2015 | 2014 | 2015 | 2014 | JUN 2015 | 2014 | |
| Net sales | 165,073 | 105,833 | 77,342 | 51,856 | 344,457 | 285,217 |
| Operating profit/loss | 30,957 | 8,368 | -2,114 | 2,142 | 101,949 | 79,360 |
| Operating margin, % | 18.8 | 7.9 | Neg | 4.1 | 29.6 | 27.8 |
| Profit/loss for the period | 22,418 | 5,935 | -2,605 | 1 | 76,315 | 59,832 |
| Earnings/loss per share, SEK | 0.65 | 0.17 | -0.08 | 0.00 | 2.23 | 1.75 |
| Share price at the end of the period, SEK | 108.00 | 39.60 | 108.00 | 39.60 | 108.00 | 53.00 |
The information in the interim report is such that RaySearch is required to disclose publicly in accordance with the Swedish Securities and Clearing Operations Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication on August 28, 2015 at 7:45 a.m.
Our success with RayStation® continues and the strong start to the year remains unabated. During the first half of the year, order intake for RayStation® more than doubled to SEK 124.4 M (59.1) and in the third quarter, we have secured several key orders from some of the world's largest and most respected cancer clinics, including MD Anderson and the University of Florida Health Proton Therapy Institute in the US, and Gustave Roussy in France. We secured these orders in direct competition with our main competitors, which I consider firm confirmation that our system offers major benefits. Our sales success is based on RayStation's high calculation speed, automated workflow, advanced support for adaptive radiation therapy, unique multi-criteria optimization and user-friendly interface. More and more highly respected customers can now confirm that RayStation's advanced and unique technology helps them improve their radiation therapy and use existing radiation equipment more efficiently.
To date, more than 230 cancer clinics in some 20 countries have purchased RayStation®. Meanwhile, since there are more than 8,000 radiation-therapy clinics worldwide, our growth potential remains very strong.
We are continuing to expand our sales and support organization as planned and during the first half of the year, we increased the number of sales and support personnel in our subsidiaries in Europe and the US, and signed distribution agreements with such countries as Turkey, Saudi Arabia and Jordan.
The high volume growth for RayStation® now accounts for more than 70% of our sales. In the first half of the year, revenues from RayStation® rose approximately 129 percent to SEK 116.6 M (50.9), while sales via partners declined slightly to SEK 48.5 M (55.1). Overall, revenues rose 56.0 percent to SEK 165.1 M (105.8) and operating profit increased to SEK 31.0 M (8.4). These figures represent the highest-ever sales and earnings for the first half-year.
Sales of RayStation® have gained real momentum, and the system is firmly established in all major markets around the world. Our sales and earnings will continue to vary from quarter to quarter, since deliveries are subject to major fluctuations. However, I take great pleasure in confirming that our sales have reached record levels for seven consecutive quarters, compared with year-on-year quarters. We also note how this growth is continuing unabated in the third quarter, which we hope will lead to improved earnings for the second half of the year, which is usually considerably stronger than the first half of the year. This will provide a stable base for a continued focus on RayStation®.
During the spring and summer, we were also able to confirm interest in the Oncology Information System (OIS) that we are developing, known as RayCare®. A radiation therapy clinic essentially needs two software platforms for its business activities: an information system and a treatment planning system. RayCare® and RayStation® will enable us to provide the entire infrastructure for a clinic's information management and treatment planning. The launch of RayCare® in 2017 will present us with new opportunities, both clinically and commercially, which is also confirmed by our long-term collaboration agreement with Accuray regarding RayCare®.
RaySearch celebrated its 15th anniversary in June and, in connection with this landmark, I can confirm that the company has never experienced such powerful momentum, neither internally within research and development, for example, nor externally in the global market. This gives us an excellent platform for continued success. We have now entered a new and exciting phase of development with an ever-growing customer base and new strategic opportunities. I therefore look forward to the future with great confidence.
Stockholm, August 28, 2015
Johan Löf President and CEO of RaySearch Laboratories AB (publ)
In January 2015, it was announced that CFO, Anders Martin-Löf, had decided to leave RaySearch in April to become CFO of another company. In March, Peter Thysell was appointed Interim CFO and he was subsequently appointed permanent CFO as of August. In June, Victoria Sörving was appointed new General Counsel, Kjell Eriksson new Chief Science Officer and Björn Hårdemark Deputy CEO. All will join executive management.
In February, it was announced that Westdeutsches Protontherapiezentrum Essen (WPE) in Germany was the first proton center in Europe to use RayStation® for clinical treatments.
In May, it was announced that the Ackerman Cancer Center in Jacksonville, USA, had started to use RayStation® for clinical proton therapy treatments together with Mevion S250 equipment.
In May, it was announced that the Texas Center for Proton Therapy had chosen the RayStation® treatment planning system. RayStation® has also qualified as an approved treatment planning system for the US Oncology Network, a national collaboration in the US encompassing some 100 radiation therapy clinics.
In July, it was announced that RaySearch and Accuray Inc. had signed a long-term collaboration agreement regarding the RayCare® Oncology Information System (OIS), which RaySearch is currently developing. Under the agreement, Accuray will be able to offer RayCare® in several major radiation therapy markets with a fully integrated solution for its TomoTherapy® and CyberKnife®.
In August, it was announced that RaySearch with RayStation®, in direct competition with the company's main competitors, had secured several major orders with some of the world's largest and most respected cancer clinics, including
In the second quarter of 2015, sales rose 49.1 percent year-on-year to SEK 77.3 M (51.9). Sales consist of license revenues from sales of RayStation® and sales of software modules via partners, as well as support revenues. In the second quarter of 2015, license revenues amounted to SEK 66.7 M (45.5). In the same period, support revenues increased to SEK 10.7 M (6.4). The sales increase is due to the sharp growth in sales of RayStation®. At the same time, sales via partners continued to decline.
Order intake excluding service agreements amounted to SEK 72.0 M (46.8). Of the order intake, RayStation® accounted for SEK 55.3 M (24.4). At June 30, the order backlog for RayStation® was SEK 33.8 M (66.5).
The company is dependent on exchange-rate trends in the USD and EUR against the SEK, since invoicing is mainly denominated in USD and EUR, while most of the costs are in SEK. During the first quarter of 2015, revenues in USD were recognized at an average exchange rate of SEK 8.42, compared with SEK 6.60 in the year-earlier period. During the second quarter of 2015, revenues in EUR were recognized at an average exchange rate of SEK 9.30, compared with SEK 9.05 in the year-earlier period. Accordingly, currency effects had a positive impact on sales. At unchanged exchange rates, sales would have increased 27.3 percent year-on-year.
During the quarter, the operating result deteriorated to a loss of SEK 2.1 M (profit: 2.1), corresponding to a negative operating margin of 2.7 percent (pos: 4.13). Operating expenses, excluding exchange-rate gains and losses, increased SEK 23.0 M to SEK 73.2 M, compared with the year-earlier quarter. The deterioration in earnings is largely a result of increased operating expenses due to the focus on sales of RayStation® and the development of RayCare®. This has led to higher costs for marketing and additional personnel in sales, service, research and development. In addition, the head office in Stockholm has relocated to new, purpose-built premises.
Other operating income and expenses refers to exchange-rate gains and losses, with the net of these amounting to an expense of SEK 4.1 M (income: 1.9) in the second quarter of 2015. The decrease is mainly due to the major portion of accounts receivable that are denominated in USD, which weakened in the second quarter compared with the end of the first quarter.
At 30 June 2015, some 92 (80) employees were engaged in research and development. Research and development costs include payroll costs, consulting fees, computer equipment and premises. Before capitalization and amortization of development expenditures, research and development costs totaled SEK 34.5 M (24.2).
In the second quarter of 2015, capitalized development expenditure amounted to SEK 18.6 M (13.9) and in the same period, amortization of capitalized development expenditure amounted to SEK 12.6 M (14.6). After adjustments for capitalization and amortization of development costs, research and development costs totaled SEK 28.5 M (24.9). Loss after tax for the quarter was SEK 2.6 M (0.0).
In the second quarter of 2015, license revenues were distributed as follows: North America, 44 percent (37); Asia, 16 percent (33); Europe and the rest of the world, 40 percent (30).
During the first half of 2015, sales rose 56.0 percent year-on-year and amounted to SEK 165.1 M (105.8). License revenues during the first half of 2015 amounted to SEK 144.0 M (92.3), and rose due to increased revenues from direct sales of RayStation®. Order intake excluding service agreements amounted to SEK 158.3 M (101.6). Of the order intake, RayStation® accounted for SEK 124.4 M (59.1). At June 30, the order backlog for RayStation® was SEK 33.8 M (66.5). Support revenues in the first half of 2015 rose to SEK 21.1 M (13.6).
During the first half of 2015, revenues in USD were recognized at an average exchange rate of SEK 8.38, compared with SEK 6.58 in the year-earlier period. During the first half of 2015, revenues in EUR were recognized at an average exchange rate of SEK 9.34, compared with SEK 8.98 in the year-earlier period. Accordingly, currency effects had a positive impact on sales. At unchanged exchange rates, sales would have increased 33.1 percent year-on-year.
A sensitivity analysis of currency exposure indicates that the impact of a +/-10 percent change in the average USD exchange rate on operating profit for the first half of 2015 was +/- SEK 17.9 M, and that the corresponding effect of a +/-10 percent change in the average EUR exchange rate was about +/- SEK 6.2 M. The company pursues the currency policy established by the Board of Directors, whereby exchange-rate changes are not hedged.
During the first half of 2015, operating profit amounted to SEK 31.0 M (8.4), representing an operating margin of 18.8 percent (7.9). Operating expenses, excluding exchange-rate gains and losses, increased SEK 35.8 M to SEK 131.2 M, compared with the year-earlier period. The increase in operating expenses was mainly due to higher costs for marketing and personnel for sales and service resulting from the focus on direct sales of RayStation®, and personnel for the development of RayCare®. In addition, the head office in Stockholm has relocated to new, purpose-built premises.
Other operating income and expenses refers to exchange-rate gains and losses, with the net of these amounting to income of SEK 3.8 M (1.7) in the first half of 2015. The increase is mainly due to the major portion of accounts receivable that are denominated in USD, which strengthened during the period.
Before capitalization and amortization of development expenditures, research and development costs totaled SEK 62.9 M (47.5).
During the first half of 2015, capitalized development costs amounted to SEK 35.0 M (28.3). Amortization of capitalized development expenditure in the first half of 2015 amounted to SEK 25.3 M (29.1). After adjustments for capitalization and amortization of development costs, research and development costs totaled SEK 53.2 M (48.3).
Amortization of intangible fixed assets in the first half of 2015 amounted to SEK 25.3 M (29.1) and depreciation of tangible fixed assets totaled SEK 2.4 M (0.6). Total amortization and depreciation during the first half of 2015 amounted to SEK 27.7 M (29.7). Amortization and depreciation primarily pertained to capitalized development expenditure.
For the first half of 2015, profit after tax was SEK 22.4 M (5.9), corresponding to earnings per share before and after dilution of SEK 0.65 (0.17)
In the first half of 2015, license revenues were distributed as follows: North America, 42 percent (31); Asia, 16 percent (39); Europe and the rest of the world, 42 percent (30).
Revenues from RaySearch are subject to seasonal variations that are typical of the industry, whereby the fourth quarter is strongest, while the second quarter is usually relatively weak.
In the first half of 2015, cash flow from operating activities rose to SEK 57.1 M (19.0), mainly due to improved earnings. Cash flow from investing activities was a negative SEK 57.7 M (neg: 30.3), of which investments in tangible fixed assets amounted to a negative SEK 22.6 M (neg: 2.0), primarily pertaining to the head office's new premises and a new exhibition booth. In addition, investments in intangible fixed assets amounted to a negative SEK 35.1 M (neg: 28.3), and comprised capitalized development costs.
Cash flow for the period amounted to a negative SEK 2.3 M (neg: 11.3), and at June 30, 2015, cash and cash equivalents amounted to SEK 53.9 M, compared with SEK 27.0 M at June 30, 2014. At June 30, 2015, current receivables totaled SEK 156.8 M, compared with SEK 94.6 M at June 30, 2014. The receivables mainly comprise accounts receivable, and the increase was due mainly to a sharp rise in sales and to the appreciation of the USD against SEK.
In November 2014, the company's credit facility was expanded from SEK 30 M to SEK 50 M, whereby chattel mortgages were increased to SEK 50 M. The credit facility comprises an overdraft facility of SEK 25 M and a revolving loan of up to SEK 25 M, which expires on November 4, 2017. Within the terms of the revolving loan, an amount of SEK 25 M has been borrowed until February 2016.
Of the company's credit facility of SEK 25 M, SEK 3.8 M has been blocked as collateral for bank guarantees totaling EUR 0.4 M to MedAustron.
The provision pertaining to the settlement with Prowess was reclassified as a liability during 2014, as a result of the signed settlement. The liability is in USD and it has been discounted since it does not carry interest. Currency and discounting effects during the year had a negative impact of SEK 0.2 M on profit from financial items.
RaySearch's financial assets and liabilities comprise accounts receivable, cash and cash equivalents, accrued income, accrued expenses, bank loans, accounts payable and a liability attributable to the settlement agreement signed with Prowess in April 2014. The liability pertaining to the settlement is discounted, while other financial assets and liabilities have short terms. Accordingly, the fair values of all financial instruments are deemed to correspond approximately to the carrying amounts. RaySearch has not applied net accounting to any financial assets or liabilities and has no agreements that permit offsetting.
During the first half of 2015, investments in intangible fixed assets amounted to SEK 35.1 M (28.3) and comprised capitalized development costs for RayStation® and RayCare®. Investments in tangible fixed assets amounted to SEK 34.9 M (2.0) and primarily pertained to the head office's new premises and a new exhibition booth.
At the end of the first half-year, the Group had 153 (125) employees, of whom 128 were based in Sweden and 25 in foreign subsidiaries. The average number of employees in the Jan-June 2015 period was 144 (119).
Since the Parent Company's operations match the Group's operations in all material respects, the comments for the Group are also largely relevant for the Parent Company. Development expenditure and adjustments related to financial leasing are capitalized in the Group but not in the Parent Company.
| AMOUNTS IN SEK 000S | JAN-JUN | APR–JUN | JUL 2014- | FULL-YEAR | ||
|---|---|---|---|---|---|---|
| 2015 | 2014 | 2015 | 2014 | JUN 2015 | 2014 | |
| Net sales | 165,073 | 105,833 | 77,342 | 51,856 | 344,457 | 285,217 |
| Cost of goods sold1) | -6,706 | -3,832 | -2,173 | -1,447 | -14,501 | -11,627 |
| Gross profit | 158,367 | 102,001 | 75,169 | 50,409 | 329,956 | 273,590 |
| Other operating income | 11,699 | 3,902 | - | 3,249 | 24,600 | 16,803 |
| Selling expenses | -58,088 | -32,827 | -33,737 | -18,597 | -103,694 | -78,433 |
| Administrative expenses | -19,867 | -14,190 | -10,962 | -6,680 | -36,413 | -30,736 |
| Research and development expenditure | -53,228 | -48,346 | -28,500 | -24,911 | -99,951 | -95,069 |
| Other operating expenses | -7,926 | -2,172 | -4,084 | -1,328 | -12,549 | -6,795 |
| Operating profit/loss | 30,957 | 8,368 | -2,114 | 2,142 | 101,949 | 79,360 |
| Result from financial items | -1,095 | -302 | -606 | -364 | -1,452 | -659 |
| Profit/loss before tax | 29,862 | 8,066 | -2,720 | 1,778 | 100,497 | 78,701 |
| Tax | -7,444 | -2,131 | 115 | -1,777 | -24,182 | -18,869 |
| Profit for the period2) | 22,418 | 5,935 | -2,605 | 1 | 76,315 | 59,832 |
| Other comprehensive income | ||||||
| Items to be reclassified to profit or loss Translation difference of foreign operations for the |
||||||
| period | -1,555 | -1,084 | 1,279 | -1,055 | -5,356 | -4,885 |
| Items not to be reclassified to profit or loss | - | - | - | - | - | - |
| Comprehensive income for the period2) | 20,863 | 4,851 | -1,326 | -1,054 | 70,959 | 54,947 |
| Earnings/loss per share before and after dilution (SEK) | 0.65 | 0.17 | neg | 0.00 | 2.23 | 1.75 |
1) Does not include amortization of capitalized development costs. Depreciation and capitalization of development costs is included in research and development costs.
2) 100% attributable to Parent Company shareholders.
| AMOUNTS IN SEK 000S | 2015-06-30 | 2014-06-30 | 2014-12-31 |
|---|---|---|---|
| ASSETS | |||
| Intangible fixed assets | 173,801 | 165,855 | 164,081 |
| Tangible fixed assets | 45,482 | 7,060 | 12,951 |
| Total fixed assets | 219,283 | 172,915 | 177,032 |
| Current receivables | 156,805 | 94,573 | 156,636 |
| Cash and cash equivalents | 53,906 | 27,010 | 56,085 |
| Total current assets | 210,711 | 121,583 | 212,721 |
| TOTAL ASSETS | 429,994 | 294,498 | 389,753 |
| EQUITY AND LIABILITIES | |||
| Equity | 272,411 | 201,452 | 251,548 |
| Deferred tax liabilities | 42,863 | 36,488 | 40,724 |
| Long-term liabilities | 53,086 | 23,050 | 41,096 |
| Accounts payable | 7,904 | 7,326 | 9,034 |
| Other current liabilities | 53,730 | 26,182 | 47,351 |
| TOTAL EQUITY AND LIABILITIES | 429,994 | 294,498 | 389,753 |
| Pledged assets | 53,800 | 55,400 | 53,800 |
| Contingent liabilities | - | - | - |
| AMOUNTS IN SEK 000S | JAN-JUN | APR-JUN | FULL-YEAR | ||
|---|---|---|---|---|---|
| 2015 | 2014 | 2015 | 2014 | 2014 | |
| Profit/loss before tax | 29,862 | 8,066 | -2,720 | 1,778 | 78,701 |
| Adjusted for | |||||
| non-cash items1) | 25,744 | 26,941 | 18,726 | 12,628 | 46,315 |
| Taxes paid | -5,327 | -8,211 | -3,519 | -4,412 | -15,247 |
| Cash flow from operating activities before changes in | |||||
| working capital | 50,279 | 26,796 | 12,487 | 9,993 | 109,769 |
| Cash flow from changes in working capital | 6,830 | -7,762 | 5,971 | -2,847 | -59,496 |
| Cash flow from operating activities | 57,109 | 19,034 | 18,458 | 7,146 | 50,273 |
| Cash flow from investing activities | -57,712 | -30,316 | -27,546 | -15,014 | -57,844 |
| Cash flow from financing activities | -1,700 | - | -1,004 | - | 24,345 |
| Cash flow for the period | -2,303 | -11,282 | -10,092 | -7,868 | 16,774 |
| Cash and cash equivalents at the beginning of the period | 56,085 | 38,231 | 64,540 | 34,749 | 38,231 |
| Exchange-rate difference in cash and cash equivalents | 124 | 61 | -542 | 129 | 1,080 |
| Cash and cash equivalents at the end of the period | 53,906 | 27,010 | 53,906 | 27,010 | 56,085 |
1)These amounts include amortization of capitalized development costs of SEK 25.3 M (29.1) and exchange-rate losses of SEK 2.8 M (loss: 3.1).
| AMOUNTS IN SEK 000S | JAN–JUN | FULL-YEAR | |
|---|---|---|---|
| 2015 | 2014 | 2014 | |
| Opening balance | 251,548 | 196,601 | 196,601 |
| Profit/loss for the period | 22,418 | 5,935 | 59,832 |
| Translation difference for the period | -1,555 | -1,084 | -4,885 |
| Closing balance | 272,411 | 201,452 | 251,548 |
| AMOUNTS IN SEK 000S | JAN-JUN | FULL-YEAR | ||
|---|---|---|---|---|
| 2015 | 2014 | 2013 | 2014 | |
| Net sales | 165,073 | 105,833 | 75,400 | 285,217 |
| Operating profit/loss | 30,957 | 8,368 | -11,122 | 79,360 |
| Operating margin, % | 18.8 | 7.9 | neg | 27.8 |
| Profit margin, % | 18.1 | 7.6 | neg | 27.6 |
| Profit/loss for the period | 22,418 | 5,935 | -10,824 | 59,832 |
| Earnings per share, SEK | 0.65 | 0.17 | -0.32 | 1.75 |
| Return on capital employed, % | 12.4 | 4.2 | 8.0 | 33.7 |
| Return on equity, % | 9.5 | 2.9 | 6.6 | 26.7 |
| Equity/assets ratio, % | 63.4 | 68.4 | 73.1 | 64.5 |
| Total number of shares | 34,282,773 | 34,282,773 | 34,282,773 | 34,282,773 |
| Adjusted equity per share at the end of the period, SEK | 7.95 | 5.88 | 6.00 | 7.34 |
| Share price at the end of the period, SEK | 108.00 | 39.60 | 26.20 | 53.00 |
For definitions of key figures, see page 48 of the 2014 Annual Report.
| AMOUNTS IN SEK 000S | JAN-JUN | APR–JUN | FULL-YEAR | ||
|---|---|---|---|---|---|
| 2015 | 2014 | 2015 | 2014 | 2014 | |
| Net sales | 138,906 | 90,104 | 64,064 | 37,609 | 250,363 |
| Cost of goods sold | -4,084 | -1,385 | -891 | -130 | -7,223 |
| Gross profit | 134,822 | 88,719 | 63,173 | 37,479 | 243,140 |
| Other operating income | 11,699 | 3,902 | - | 3,249 | 16,803 |
| Selling expenses | -36,783 | -20,429 | -22,879 | -12,209 | -50,669 |
| Administrative expenses | -20,298 | -14,179 | -11,208 | -6,677 | -30,912 |
| Research and development expenditure | -62,948 | -47,523 | -34,515 | -24,212 | -92,472 |
| Other operating expenses | -7,926 | -2,172 | -4,084 | -1,328 | -6,795 |
| Operating profit/loss | 18,566 | 8,318 | -9,513 | -3,698 | 79,095 |
| Result from financial items | -795 | -318 | -408 | -373 | 1,565 |
| Profit/loss after financial items | 17,771 | 8,000 | -9,921 | -4,071 | 80,660 |
| Appropriations | - | - | - | - | -21,029 |
| Profit/loss before tax | 17,771 | 8,000 | -9,921 | -4,071 | 59,631 |
| Tax | -4,336 | -1,905 | 1,904 | -1,905 | -13,651 |
| Profit/loss for the period | 13,435 | 6,095 | -8,017 | -5,976 | 45,980 |
| AMOUNTS IN SEK 000S | JAN-JUN | APR-JUN | FULL-YEAR | ||
|---|---|---|---|---|---|
| 2015 | 2014 | 2015 | 2014 | 2014 | |
| Profit/loss for the period | 13,435 | 6,095 | -8,017 | -5,976 | 45,980 |
| Other comprehensive income | - | - | - | - | - |
| Comprehensive income/loss for the period | 13,435 | 6,095 | -8,017 | -5,976 | 45,980 |
| AMOUNTS IN SEK 000S | JUNE 30, 2015 | JUNE 30, 2014 | DEC. 31, 2014 |
|---|---|---|---|
| ASSETS | |||
| Tangible fixed assets | 27,839 | 5,520 | 6,975 |
| Financial fixed assets | 2,493 | 2,493 | 2,493 |
| Total fixed assets | 30,332 | 8,013 | 9,468 |
| Current receivables | 187,952 | 130,258 | 185,239 |
| Cash and cash equivalents | 42,533 | 20,412 | 47,935 |
| Total current assets | 230,485 | 150,670 | 233,174 |
| TOTAL ASSETS | 260,817 | 158,683 | 242,642 |
| EQUITY AND LIABILITIES | |||
| Equity | 149,647 | 96,328 | 136,213 |
| Untaxed reserves | 21,029 | - | 21,029 |
| Provisions | - | - | 36,853 |
| Long-term liabilities | 37,676 | 23,050 | - |
| Accounts payable | 9,126 | 8,057 | 9,823 |
| Other current liabilities | 43,339 | 31,248 | 38,724 |
| TOTAL EQUITY AND LIABILITIES | 260,817 | 158,683 | 242,642 |
| Pledged assets Contingent liabilities |
53,800 - |
55,400 - |
53,800 - |
This condensed interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the applicable provisions of the Swedish Annual Accounts Act. The Parent Company's financial statements have been prepared pursuant to Chapter 9 of the Swedish Annual Accounts Act, Interim Financial Reporting. The same accounting policies and measurement bases applied in the most recent Annual Report have been used to prepare the Group and Parent Company accounts. New or revised IFRS standards during 2015 have not affected RaySearch during the period and no known changes are expected to affect RaySearch in 2015.
RaySearch's financial policy governing the management of financial risks has been established by the Board of Directors and represents a framework of guidelines and rules in the form of risk mandates and limits for financial activities. RaySearch is primarily affected by exchange-rate risk. The predominant part of RaySearch's net sales is denominated in USD and EUR. In accordance with the established financial policy, no currency hedging is employed. The financial policy is updated at least once annually.
As a result of its activities, RaySearch is exposed to various operational risks, including the following: dependence on key persons, competition, legal disputes and strategic partnerships. For a more detailed description of RaySearch's risks and risk management, refer to page 27 of the 2014 Annual Report. No significant changes have been made to the risk assessment compared with the 2014 Annual Report.
No transactions between RaySearch and related parties materially affected the company's position and earnings during the period.
Preparation of the interim report requires that company management makes estimates that affect the carrying amounts of assets, liabilities, revenues and expenses. The actual outcome could deviate from these estimates. The critical sources of uncertainty in the estimates are the same as those in the most recent Annual Report.
This interim report has not been reviewed by the company's auditors.
The Board of Directors and President give their assurance that the six-month report provides a true and fair view of the Group and Parent Company's operation, position and earnings, and describes the significant risks and uncertainties facing the Parent Company and the companies included in the Group.
Stockholm, August 28, 2015
Erik Hedlund Johan Löf
Chairman of the Board President and Board member
Carl Filip Bergendal Hans Wigzell Board member Board member
Johan Löf, President Tel: Tel: +46 8 510 530 00 [email protected]
RaySearch Laboratories AB (publ) Corporate Registration Number 556322-6157 Sveavägen 44 SE-111 34 Stockholm, Sweden
| Interim report for the third quarter | November 25, 2015 |
|---|---|
| Year-end report | February 18, 2016 |
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch's products are distributed through licensing agreements with leading medical technology companies such as Philips, IBA Dosimetry, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch's software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on Nasdaq Stockholm.
More information about RaySearch is available at www.raysearchlabs.com.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.